ALVO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of -4.62% compared to Alvotech's net margin of 21.47%. Alvotech's return on equity of -- beat Johnson & Johnson's return on equity of 33.27%.

Alvotech has a consensus price target of $22.17, signalling upside risk potential of 377.73%. On the other hand Johnson & Johnson has an analysts' consensus of $212.00 which suggests that it could grow by 3.72%. Given that Alvotech has higher upside potential than Johnson & Johnson, analysts believe Alvotech is more attractive than Johnson & Johnson.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.341, suggesting its less volatile than the S&P 500 by 65.861%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.52% to investors and pays a quarterly dividend of $1.30 per share. Alvotech pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.8% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Alvotech quarterly revenues are $113.7M, which are smaller than Johnson & Johnson quarterly revenues of $24B. Alvotech's net income of -$5.3M is lower than Johnson & Johnson's net income of $5.2B. Notably, Alvotech's price-to-earnings ratio is 20.15x while Johnson & Johnson's PE ratio is 19.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.56x versus 5.38x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Sofgen Pharma SA has a net margin of -4.62% compared to Alvotech's net margin of --. Alvotech's return on equity of -- beat Sofgen Pharma SA's return on equity of --.

Alvotech has a consensus price target of $22.17, signalling upside risk potential of 377.73%. On the other hand Sofgen Pharma SA has an analysts' consensus of -- which suggests that it could grow by 7042.86%. Given that Sofgen Pharma SA has higher upside potential than Alvotech, analysts believe Sofgen Pharma SA is more attractive than Alvotech.

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Sofgen Pharma SA has a beta of 62.945, suggesting its more volatile than the S&P 500 by 6194.533%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sofgen Pharma SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Sofgen Pharma SA pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are larger than Sofgen Pharma SA quarterly revenues of --. Alvotech's net income of -$5.3M is higher than Sofgen Pharma SA's net income of --. Notably, Alvotech's price-to-earnings ratio is 20.15x while Sofgen Pharma SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.56x versus 0.02x for Sofgen Pharma SA. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -4.62% compared to Alvotech's net margin of 38.89%. Alvotech's return on equity of -- beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Alvotech has a consensus price target of $22.17, signalling upside risk potential of 377.73%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $824.69 which suggests that it could grow by 3.53%. Given that Alvotech has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Alvotech is more attractive than Regeneron Pharmaceuticals, Inc..

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.44% to investors and pays a quarterly dividend of $0.88 per share. Alvotech pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Alvotech's net income of -$5.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Alvotech's price-to-earnings ratio is 20.15x while Regeneron Pharmaceuticals, Inc.'s PE ratio is 19.07x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.56x versus 6.16x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cartesian Therapeutics, Inc. has a net margin of -4.62% compared to Alvotech's net margin of -7942.92%. Alvotech's return on equity of -- beat Cartesian Therapeutics, Inc.'s return on equity of --.

Alvotech has a consensus price target of $22.17, signalling upside risk potential of 377.73%. On the other hand Cartesian Therapeutics, Inc. has an analysts' consensus of $35.57 which suggests that it could grow by 333.8%. Given that Alvotech has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Alvotech is more attractive than Cartesian Therapeutics, Inc..

Alvotech has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Cartesian Therapeutics, Inc. has a beta of 0.532, suggesting its less volatile than the S&P 500 by 46.774%.

Alvotech has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cartesian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alvotech pays -- of its earnings as a dividend. Cartesian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Alvotech quarterly revenues are $113.7M, which are larger than Cartesian Therapeutics, Inc. quarterly revenues of $452K. Alvotech's net income of -$5.3M is higher than Cartesian Therapeutics, Inc.'s net income of -$35.9M. Notably, Alvotech's price-to-earnings ratio is 20.15x while Cartesian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alvotech is 2.56x versus 91.48x for Cartesian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.